Investigational drugs in thrombotic thrombocytopenic purpura

Bibliography

• Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc NY Pathol Soc 1924;24:21-4
   Google Scholar
• Tsai H-M. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol 2010;91:1-19
   PubMed Web of Science ®Google Scholar
• Kiss JE. Thrombotic thrombocytopenic purpura: recognition and management. Int J Hematol 2010;91:36-45
   PubMed Web of Science ®Google Scholar
• Zipfel PF, Heinen S, Skerka C. Thrombotic microangiopathies: new insights and new challenges. Curr Opin Nephrol Hypertens 2010;19:372-8
   PubMed Web of Science ®Google Scholar
• Lotta LA, Garagiola I, Palla R, ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat 2010;31:11-19
   PubMed Web of Science ®Google Scholar
• Noris M, Remuzzi G. Genetics and genetic testing in haemolytic syndrome/thrombotic thrombocytopenic purpura. Semin Nephrol 2010;30:395-408
   PubMed Web of Science ®Google Scholar
• Moake JL, Rudy CK, Troll JH, Unusually large plasma factor VIII, von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982;307:1432-5
   PubMed Web of Science ®Google Scholar
• Tsai H-M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996;87:4235-44
   PubMed Web of Science ®Google Scholar
• Furlan M, Robles R, Laemmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996;87:4223-34
   PubMed Web of Science ®Google Scholar
• Kokame K, Miyata T. Genetic defects leading to hereditary thrombotic thrombocytopenic purpura. Semin Hematol 2004;41:34-40
   PubMed Web of Science ®Google Scholar
• Moake JL. Thrombotic microangiopathies. N Engl J Med 2002;347:589-600
   PubMed Web of Science ®Google Scholar
• Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008;112:11-18'
   PubMed Web of Science ®Google Scholar
• Coppo P, Wolf M, Veyradier A, Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol 2006;132:66-74
   PubMed Web of Science ®Google Scholar
• Ferrari S, Scheiflinger F, Rieger M, Prognostic value of anti-ADMTS13 antibody features (Ig isotype, titre, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity. Blood 2007;109:2815-22
   PubMed Web of Science ®Google Scholar
• Zheng XL, Wu HM, Shang D, Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica 2010;95:1555-62
   PubMed Web of Science ®Google Scholar
• Kremer Hovinga JA, Veseley SK, Terrel DR, Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010;115:1500-11
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Yagi H, Ishizashi H, The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Sem Hematol 2004;41:68-74
   PubMed Web of Science ®Google Scholar
• Foley SR, Webert K, Arnold DM, A Canadian phase II study evaluating the efficacy of rituximab in the management of patients with relapsed/refractory thrombotic thrombocytopenic purpura. Kidney Int Suppl 2009;75:S55-8
   Google Scholar
• Feys HB, Canciani MT, Peyvandi F, ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol 2007;138:534-40
   PubMed Web of Science ®Google Scholar
• Feys HB, Deckmyn H, Vanhoorelbeke K. ADAMTS13 in health and disease. Acta Haematol 2009;121:183-5
   PubMed Web of Science ®Google Scholar
• George JN. How I treat patients with thrombotic thrombocytopenic purpura. Blood 2010;116:4060-9
   PubMed Web of Science ®Google Scholar
• Lammle B, Kremer-Hovinga JA, George JN. Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease. Haematologica 2008;93:172-7
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Lavoretano S, Palla R, ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008;93:232-9
   PubMed Web of Science ®Google Scholar
• Bukowski RM, King JW, Hewlett JS. Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura. Blood 1977;50:413-17
   PubMed Web of Science ®Google Scholar
• Byrnes JJ, Khurana M. Treatment of thrombotic thrombocytopenic purpura with plasma. N Engl J Med 1977;297:1386-9
   PubMed Web of Science ®Google Scholar
• Byrnes JJ, Lian ECY. Recent therapeutic advances in thrombotic thrombocytopenic purpura. Semin Thromb Hemost 1979;5:199-215
   PubMed Web of Science ®Google Scholar
• Rock GA, Shumak KH, Buskard NA, Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991;325:393-7
   PubMed Web of Science ®Google Scholar
• Henon P. Treatment of thrombotic thrombocytopenic purpura. Results of a multicenter randomized clinical study. Presse Med 1991;20:1761-7
   PubMed Web of Science ®Google Scholar
• Rock G, Anderson D, Clark W, Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. Br J Haematol 2005;129:79-86
   PubMed Web of Science ®Google Scholar
• Zeigler ZR, Shadduck RK, Gryn JF, Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP). J Clin Apher 2001;16:19-22
   PubMed Web of Science ®Google Scholar
• Owens MR, Sweeney JD, Tahhan RH, Fortkolt P. Influence of type of exchange fluid on survival in therapeutic apheresis for thrombotic thrombocytopenic purpura. J Clin Apher 1995;10:178-82
   PubMed Web of Science ®Google Scholar
• Rock G, Shumak KH, Sutton DM, Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group. Br J Haematol 1996;94:383-6
   PubMed Web of Science ®Google Scholar
• Altuntas F, Aydogdu I, Kabukcu S, Therapeutic plasma exchange for the treatment of thrombotic thrombocytopenic purpura: a retrospective multicenter study. Transfus Apher Sci 2010;36:57-67
   Google Scholar
• Edel E, Al-Ali HK, Seeger S, Efficacy and safety profile of solvent/detergent plasma in the treatment of acute thrombotic thrombocytopenic purpura: a single-center experience. Transfus Med Hemother 2010;37:13-19
   PubMed Web of Science ®Google Scholar
• Alvarez-Larran A, Del Rio J, Ramirez C, Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang 2004;86:246-51
   PubMed Web of Science ®Google Scholar
• Mintz PD, Neff A, MacKenzie M, A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 2006;46:1693-704
   PubMed Web of Science ®Google Scholar
• De la Rubia J, Arriaga F, Linares D, Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Br J Haematol 2001;114:721-3
   PubMed Web of Science ®Google Scholar
• Bramlage CP, Schroder K, Bramlage P, Predictors of complications in therapeutic plasma exchange. J Clin Apher 2009;24:225-31
   PubMed Web of Science ®Google Scholar
• Scully M, Longair I, Flynn M, Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura. Vox Sang 2007;93:154-8
   PubMed Web of Science ®Google Scholar
• Mc Carthy LJ, Dlott JS, Orazi A, Thrombotic thrombocytopenic purpura: yesterday, today, tomorrow. Ther Apher Dial 2004;8:80-6
   PubMed Web of Science ®Google Scholar
• Bobbio-Pallavicini E, Gugliotta L, Centurioni R, Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP. Haematologica 1997;82:429-35
   PubMed Web of Science ®Google Scholar
• Bennett CL, Weinberg PD, Rozemberg-Ben-Dror K, Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med 1998;128:541-4
   PubMed Web of Science ®Google Scholar
• Rosove MH, Ho WG, Goldfinger D. Ineffectiveness of aspirin and dipyridamole in the treatment of thrombotic thrombocytopenic purpura. Ann Intern Med 1982;96:27-33
   PubMed Web of Science ®Google Scholar
• Gilbert JC, De Feo-Fraulini T, Hutabarat RM, First-in-human evaluation on anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007;116:2678-86
   PubMed Web of Science ®Google Scholar
• Mayr FB, Knobl P, Jilma B, The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo. Transfusion 2010;50:1079-87
   PubMed Web of Science ®Google Scholar
• Knobl P, Jilma B, Gilbert JC, Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura. Transfusion 2009;49:2181-5
   PubMed Web of Science ®Google Scholar
• Jilma-Stohlawetz P, Gorczyca ME, Jilma B, Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. Thromb Haemost 2011;105:545-52
   PubMed Web of Science ®Google Scholar
• Cataland SR, Peyvandi F, Mannucci PM, A randomized, double-bind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. Blood 2010;116:abstract 726
   Google Scholar
• Van Bockstaele F, Holz JB, Revets H. The development of nanobodies for therapeutic applications. Curr Opin Investig Drugs 2009;10:1212-24
   PubMed Web of Science ®Google Scholar
• Bartunek J, Barbato E, Vercruysse K, Safety and efficacy of anti-von Willebrand Factor Nanobody® ALX-0081 in stable angina patients undergoing percutaneous coronary intervention. Circulation 2010;122:A15084
   Google Scholar
• Balduini CL, Gugliotta L, Luppi M, High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study. Ann Hematol 2010;89:591-6
   PubMed Web of Science ®Google Scholar
• Bell WR, Braine HG, Ness PM, Kicker TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991;325:398-403
   PubMed Web of Science ®Google Scholar
• Rojnuckarin P, Watanaboonyongcharoen P, Akkawat B, Intragumtornchai T. The role of pulse dexamethasone in acquired idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost 2007;4:1148-50
   Web of Science ®Google Scholar
• Toyoshige M, Zaitsu Y, Okafuji K, Successful treatment of thrombotic thrombocytopenic purpura with high-dose corticosteroids. Am J Hematol 1992;41:69
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to four-dose treatment program. J Clin Oncol 1998;16:2825-33
   PubMed Web of Science ®Google Scholar
• Stasi R, Stipa E, Forte V, Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood 2002;99:3872-3
   PubMed Web of Science ®Google Scholar
• Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004;103:4424-8
   PubMed Web of Science ®Google Scholar
• Cooper N, Stasi R, Cunningham-Rundles S, The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with choric immune thrombocytopenic purpura. Br J Haematol 2004;125:232-9
   PubMed Web of Science ®Google Scholar
• Scully M, Cohen H, Cavenagh J, Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS13. Br J Haematol 2007;136:451-61
   PubMed Web of Science ®Google Scholar
• McDonald V, Liesner R, Grainger J, Acquired, noncongenital thrombotic thrombocytopenic purpura in children and adolescents: clinical management and the use of ADAMTS13 assay. Blood Coagul Fibrinolysis 2010;21:254-0
   Google Scholar
• Fakhouri F, Vernant JP, Veyradier A, Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 2005;106:1932-7
   PubMed Web of Science ®Google Scholar
• Caramazza D, Quintini G, Abbene I, Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura – haemolytic uraemic syndrome. Blood Transfus 2010;8:203-10
   PubMed Web of Science ®Google Scholar
• De la Rubia J, Moscardo F, Gomez MJ, Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study. Transfus Apher Sci 2010;43:299-303
   PubMed Web of Science ®Google Scholar
• Bresin E, Gastoldi S, Daina E, Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thromb Haemost 2009;101:233-8
   PubMed Web of Science ®Google Scholar
• Heidel F, Lipka DB, von Auer C, Addition of rituximab therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia. Thromb Haemost 2007;97:228-33
   PubMed Web of Science ®Google Scholar
• Ling HT, Field JJ, Blinder MA. Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature. Am J Hematol 2009;84:418-21
   PubMed Web of Science ®Google Scholar
• Lombardi AM, de Marinis GB, Scandellari R, Clinical biological remission induced by rituximab in acute refractory chronic relapsing TTP. Thromb Res 2010;126:e154-6
   PubMedGoogle Scholar
• Chemnitz JM, Uener J, Hallek M, Scheid C. Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab. Ann Hematol 2010;89:1029-33
   PubMed Web of Science ®Google Scholar
• McDonald V, Manns K, Mackie IJ, Rituximab pharmacokinetics during the treatment of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost 2010;8:1201-8
   PubMed Web of Science ®Google Scholar
• Elliott MA, Heit JA, Pruthi RK, Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Eur J Haematol 2009;83:365-72
   PubMed Web of Science ®Google Scholar
• Scully M, Cavenagh JD, Hunt B, A phase II study to assess the safety, efficacy and tolerability of rituximab (Mabthera) in combination with plasma-exchange in patients with acute thrombotic thrombocytopenic purpura (TTP). Blood 2010;116:A3699
   Google Scholar
• Kiedorf H, Maurin N, Heintz B. Cyclosporine for thrombotic thrombocytopenic purpura. Ann Intern Med 1993;118:987-8
   PubMed Web of Science ®Google Scholar
• Cataland SR, Jin M, Ferketich AK, An evaluation of ciclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 2006;136:146-9
   PubMed Web of Science ®Google Scholar
• Cataland SR, Jin M, Lin S, Ciclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity. Br J Haematol 2007;139:486-93
   PubMed Web of Science ®Google Scholar
• Cataland SR, Ming J, Lin S, Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura. Am J Hematol 2008;83:911-15
   PubMed Web of Science ®Google Scholar
• Graham RM. Cyclosporine: mechanism of action and toxicity. Cleve Clin J Med 1994;61:308-13
   PubMed Web of Science ®Google Scholar
• Medina PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenic purpura hemolytic uremic syndrome. Curr Opin Hematol 2001;8:286-93
   PubMed Web of Science ®Google Scholar
• Chen J, Reheman A, Gushiken FC, N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest 2011;121:593-603
   PubMed Web of Science ®Google Scholar
• Sandilands EA, Bateman DN. Adverse reactions associated with acetylcysteine. Clin Toxicol (Phila) 2009;47:81-8
   PubMed Web of Science ®Google Scholar
• Knudsen TT, Thorsen S, Jensen SA, Dalhoff K. Effect of intravenous N-acetylcysteine infusion on haemostatic parameters in healthy subjects. Gut 2005;54:515-21
   PubMed Web of Science ®Google Scholar
• Wijeysundera DN, Karkouti K, Rao V, N-acetylcysteine is associated with increased blood loss and blood product utilization during cardiac surgery. Crit Care Med 2009;37:1929-34
   PubMed Web of Science ®Google Scholar
• Plaimauer B, Zimmermann K, Volkel D, Cloning, expression and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood 2002;100:3626-32
   PubMed Web of Science ®Google Scholar
• Antoine G, Zimmermann K, Plaimauer B, ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13. Br J Haematol 2003;120:821-4
   PubMed Web of Science ®Google Scholar
• Plaimauer B, Kremer Hovinga JA, Juno C, Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving protease activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost 2011; published online 5 February 2011; doi: 10.1111/j.1538-7836.2011.04224.x
   PubMed Web of Science ®Google Scholar
• Schulman I, Pierce M, Lukens A, Currimbhoy Z. Studies on Thrombopoiesis, I: a factor in normal human plasma required for platelet production: chronic thrombocytopenia due to its deficiency. Blood 1960;16:1350-2
   Google Scholar